Macular neurosensory retinal detachment associated with topiramate use

Morales, Alvárez; Sánchez-Vicente, J.L.; Ruedas, C. Franco; Iglesias, J. de las Morenas; Espiñeira-Periñán, M.A.; López-Herrero, F.

doi:10.1016/j.oftale.2019.07.014

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One case report hypothesized that maculopathy in one patient was induced by TPM [15]. Moreover, several case reports have demonstrated that TPM may cause retinal and macular neurosensory detachments [16,17]. We recommend that more studies be conducted to identify the association described in two of the cases above where the macular detachments resolved shortly after discontinuing TPM treatment.…”

Section: Discussionmentioning

confidence: 93%

Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system

Chen

et al. 2022

Seizure

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system

Chen

et al. 2022

Seizure

View full text Add to dashboard Cite

“…In addition to retinal striae, TPM may cause macular and retinal neurosensory detachments. Symptoms improve once TPM is discontinued [ 23 - 24 ]. In 2012, Gualtieri W and Janula J reported the first case of TPM-induced maculopathy, citing a report of a 22-year-old female who developed a neurosensory retinal detachment and macular striae six days after beginning TPM for a migraine attack.…”

Section: Reviewmentioning

confidence: 99%

“…The retinal detachment and striae resolved after the discontinuation of TPM and the use of steroids [ 25 ]. Two other articles have since been published describing this phenomenon [ 23 - 26 ].…”

Section: Reviewmentioning

confidence: 99%

The Ophthalmic Side Effects of Topiramate: A Review

Mechrgui¹,

Kanani²

2022

Cureus

View full text Add to dashboard Cite

Topiramate (TPM) is a sulfonamide drug with multiple modes of action. It inhibits carbonic anhydrase, blocks sodium channels, enhances potassium channels, and stimulates postsynaptic gamma-aminobutyric acid (GABA) receptors. Pharmacists Joe Gardocki and Bruce Maryanoff synthesized TPM for the first time in 1979. The FDA did not approve it for medical use in the US until 1996. Around 2004, it was authorized for the prevention of migraine headaches. TPM, like any medication, has several side effects. Common aftermaths include weight loss, diarrhea, dizziness, sleepiness, fatigue, and coordination issues. Some people may experience mental health issues like memory problems, confusion, and speech or language difficulties. The most well-known ocular side effects of TPM are choroidal effusion syndrome, angle-closure glaucoma, and myopic shift. Aside from these, other ophthalmic adverse effects may arise in some people, including retinal problems, uveitis, visual field defects, myokymia, and neuro-ophthalmology complications. If such complications are not identified and treated promptly, they can be severe and vision-threatening, potentially leading to permanent blindness. TPM's application as a standalone and adjunctive therapy has increased over time. In 2019, more than 10 million prescriptions of TPM were issued. Due to its extensive use, medical professionals and patients must be aware of its potential repercussions, especially ophthalmic issues. The current review paper likewise makes a step in this direction. This article's primary purpose is to educate readers by providing a comprehensive assessment of the research on TPM's ocular side effects. All the information has been collected via a thorough search of the Google Search Engine and PubMed.

show abstract

Clinical Profile and Risk Factors of Central Serous Chorioretinopathy in Al- Ain, United Arab Emirates

Jain

Kurian

Lal

et al. 2022

NEMJ

View full text Add to dashboard Cite

Background: Based on the adverse event reporting system, the authors observed unique occupational and pharmacological trends in central serous chorioretinopathy (CSC); despite being a common condition in the region, there are no large epidemiological studies. Objective: To describe the clinical profile, risk factors and co-medications of CSC in a multispecialty hospital in UAE. Methods: Hospital based retrospective, observational study in which all the confirmed cases of CSC (272) seen between 2010 and 2019 were included. Supplementary data was collected on follow up visits or through telephonic calls. Results: The male: female ratio was 17:1; low socio-economic status was (155; 73.45%), and occupations such as drivers (61; 28.9%) and outdoor laborers (59; 27.96%) were the most commonly affected. The majority (78.05%; 185) were single expatriates. Financial worries (105; 50.72%) constituted the leading cause of stress. The usage of corticosteroids (83; 30.51%), nasal decongestants (14.70%) or both (17; 6.25%) within one year was common; mostly (82; 30.14%) for rhinitis/respiratory states, though grossly under-recognized. Muscle relaxants and psychotropic medications were the other major medications used by 24 (8.82%) and 25 (9.19%) cases prior to CSC. Seven of 15 women had at least one condition that alters the endocrinal milieu: Pregnancy (3), recent child birth (1), erratic oral contraceptive intake (1), menopause with liver dysfunction (1), hormone replacement therapy for menopause and endometriosis (1), ovarian cyst and infertility (1) hypothyroidism (3), and Cushing syndrome (1). Chronic/ recurrent forms were seen in 31.08%. There were too few glaucoma patients despite both CSC and glaucoma being common among our patients. Conclusions: CSC in Al-Ain predominantly affected males with a specific occupational predisposition. Emotional distress, financial worries, allergic disorders, and endocrinal disorders (among females) were common. Adverse drug events were under-reported compared to the usage of steroid or decongestant users. Suspected pharmacological associations included drugs that modulated the vasomotor tone.

show abstract

Macular neurosensory retinal detachment associated with topiramate use

Cited by 3 publications

References 7 publications

Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system

Eye disorders associated with newer antiepileptic drugs: A real-world disproportionality analysis of FDA adverse event reporting system

The Ophthalmic Side Effects of Topiramate: A Review

Clinical Profile and Risk Factors of Central Serous Chorioretinopathy in Al- Ain, United Arab Emirates

Contact Info

Product

Resources

About